A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.
A test for a wide range of genetic risk factors could improve doctors’ ability to work out which women are at increased risk of developing breast cancer, a major study of more than 65,000 women has shown.
One of the world’s leading childhood brain tumour experts, Professor Richard Gilbertson, has been appointed as Li Ka Shing Chair of Oncology in Cambridge and Director of the Cambridge Cancer Centre. He will take up his appointment in August.
A clinical trial due to begin later this year will see scientists observing close up, in real time – and in patients – how tumours respond to new drugs.
Astronomy and oncology do not make obvious bedfellows, but the search for new stars and galaxies has surprising similarities with the search for cancerous cells. This has led to new ways of speeding up image analysis in cancer research.
A trawl through a library of more than 50,000 ‘small molecules’ has identified a potential candidate to inhibit the spread of cancer cells throughout the body. Reported today in the journal Nature Communications, the molecule targets a mechanism of tumour development that had previously been considered ‘undruggable’– in other words, extremely difficult, if not impossible, to target with a drug – and could open the door to further promising new candidates.
Launched today (26 September), Cancer Core Europe brings together six cancer centres – including the Cambridge Cancer Centre at the University of Cambridge – to link cancer research through to cancer care.
Women with breast cancer are 10 per cent more likely to survive for five years or more if they have certain immune cells near their tumour, according to new research.
Research sheds light on how tumours develop drug resistance
© 2025 University of Cambridge